Featured Research

from universities, journals, and other organizations

Quitting smokeless tobacco after heart attack may extend life expectancy

Date:
June 23, 2014
Source:
American Heart Association
Summary:
Quitting smokeless tobacco after a heart attack extends life expectancy similar to quitting smoking, researchers report. Study participants who stopped using the Swedish form of snuff after a heart attack reduced their risk of dying by nearly 50 percent.

“Snus” is moist Swedish smokeless powder tobacco.
Credit: Gabriel Arefalk, M.D.

People who stop using smokeless tobacco after a heart attack may extend their life expectancy similar to people who stop smoking, according to new research in the American Heart Association journal Circulation.

"We didn't expect to see such a strong association among those people who stopped using (smokeless tobacco)," said Gabriel Arefalk, M.D., lead researcher and cardiologist at Uppsala University Hospital in Uppsala, Sweden. "After a heart attack, no doubt smoking cessation reduces the risk of death approximately one third and is really a cornerstone of cardiac rehabilitation worldwide. For smokeless tobacco, we did not know."

This may be the first study to examine the impact of smokeless tobacco on death in heart attack survivors.

Researchers analyzed the effect of quitting the use of snus, a moist Swedish smokeless powder tobacco kept under the upper lip. It's a variant of snuff, but doesn't need to be spit out.

They reviewed data on heart attack survivors younger than 75 in Sweden in 2005-09 and identified 2,474 snus users. Of those, 675 quit using snus. During two years of follow-up, 14 snus-quitters died and 69 of those who continued using snus died. In a mathematical analysis estimating the number of people who die in 1,000 years, researchers determined that the death rate was 9.7 per 1,000 person-years at risk for snus quitters and 18.7 for snus users.

After considering factors like age, gender, other tobacco use, occupation and participation in a cardiac rehabilitation program, researchers said those who stopped using snus had nearly half the mortality risk, similar to the benefit observed with smoking cessation.

Although the study focused on snus, Arefalk said nicotine levels are comparable to levels in snuff.

Snuff use is increasing worldwide. In the largest market, the United States, about 1.7 billion cans are consumed each year. The largest concentration of a population (prevalence) using snuff is in Sweden, where 20 percent of men and 3 percent of women use snus daily.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. G. Arefalk, K. Hambraeus, L. Lind, K. Michaelsson, B. Lindahl, J. Sundstrom. Discontinuation of Smokeless Tobacco and Mortality Risk after Myocardial Infarction. Circulation, 2014; DOI: 10.1161/CIRCULATIONAHA.113.007252

Cite This Page:

American Heart Association. "Quitting smokeless tobacco after heart attack may extend life expectancy." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623161809.htm>.
American Heart Association. (2014, June 23). Quitting smokeless tobacco after heart attack may extend life expectancy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140623161809.htm
American Heart Association. "Quitting smokeless tobacco after heart attack may extend life expectancy." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623161809.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins